Navigation Links
Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
Date:7/30/2013

KING OF PRUSSIA, Pa., July 30, 2013 /PRNewswire/ -- Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today the publication of new findings related to the mechanism of action of its Angiotensin II Type 1 Receptor (AT1R) biased ligands. The publication describes work led by R. John Solaro PhD, Distinguished University Professor and Head of the Department of Physiology and Biophysics at the University of Illinois at Chicago, performed in collaboration with Trevena scientists.  The studies evaluated the molecular mechanisms of action for TRV120023, a molecule closely related to Trevena's clinical stage asset, TRV027, which is in Phase 2 testing for the treatment of acute heart failure. TRV027 is being developed by Trevena under a recently announced collaborative licensing option agreement with Forest Laboratories Inc. (NYSE: FRX).

The article, entitled "The Beta-arrestin-Biased Ligand TRV120023 Inhibits Angiotensin II-Induced Cardiac Hypertrophy While Preserving Enhanced Myofilament Response to Calcium", was published online, ahead of print, July 19, 2013, in the American Journal of Physiology - Heart and Circulatory Physiology.

Work in Dr. Solaro's laboratory showed that TRV120023 blocked cardiac hypertrophy in rats, while stimulating biochemical pathways linked to increased cardiac contractility.  TRV120023 increased the sensitivity of cardiac myofilaments to calcium, suggesting that TRV120023 and molecules like it, such as TRV027, can increase cardiac contractile force ("inotropy") through a mechanism distinct from classic inotropes, which are associated with cardiac arrhythmia and increased mortality. Dr Solaro said of the published work, "these experiments suggest that Trevena's biased ligands regulate the heart's contractile machinery through a novel mechanism which may simultaneously block cardiac dysfunction while promoting cardiac contractility"

Michael Lark Ph.D., Trevena's Chief Scientific Officer, commented that "these findings further support the hypothesis that beta-arrestin biased ligands like TRV120023 and TRV027 may offer unique benefits in treating cardiovascular disease." 

About Acute Heart Failure

The American Heart Association estimated that acute heart failure (AHF) hospitalization costs the U.S. healthcare system more than $20 billion each year in direct spending. AHF is already the leading reason for hospitalization of individuals over 65 years old in the United States, with over 1 million hospital admissions per year. AHF is also the most costly diagnosis for Medicare in the nation. Despite the significance of this problem, current therapies are not producing meaningful improvements in patient outcomes. AHF incidence is increasing globally, and both heart failure mortality and hospital re-admission following an AHF event remain extremely high.

About Trevena

Trevena, Inc. is dedicated to discovering and developing the next generation of GPCR targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. In addition to TRV027, Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand, TRV130, for post-operative pain, and discovery-stage programs for chronic pain and Parkinson's disease.

For more information, please contact:
Ros Deegan, VP Business Development, Trevena Inc., 610-354-8840 x225 (Corporate)
Kimberly Minarovich, Christensen, 917-533-3268 (Media)


'/>"/>
SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
2. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
3. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
4. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
5. eCardio Teams Up with Heart Rhythm Society for Month-Long Campaign to Raise Awareness of Cardiac Arrhythmias
6. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
7. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
8. Cardiac Science to Supply Q-Tel Data to AACVPR Cardiac Rehabilitation Registry
9. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
10. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
11. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation ... innovations for structural heart disease and critical care monitoring, ... share repurchase (ASR) agreement with Morgan Stanley & Co. ... This repurchase is part of the Company,s previously authorized ... Company,s common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  Montoya Love ... Professional in the field of Pharmaceuticals. Montoya is the ... Manufacturing ... supplies, Becton Dickinson provides healthcare institutions, clinical ... equipment throughout fifty countries across the globe. ...
Breaking Medicine Technology:
(Date:2/5/2016)... Salt Lake City, UT (PRWEB) , ... February 05, 2016 , ... ... Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, ... Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
Breaking Medicine News(10 mins):